{"id":"mydecamycin","rwe":[{"pmid":"297201","year":"1979","title":"[Comparison of the effect of ampicillin, ceftezole and mydecamycin on experimentally prepared pyoderma (author's transl)].","finding":"","journal":"Shigaku = Odontology; journal of Nihon Dental College","studyType":"Clinical Study"},{"pmid":"275736","year":"1977","title":"[A study on absorption and excretion of healthy adults given mydecamycin (medemycin) capsules or granule (author's transl)].","finding":"","journal":"Shigaku = Odontology; journal of Nihon Dental College","studyType":"Clinical Study"},{"pmid":"16149","year":"1977","title":"[Antibiotic susceptibility of Streptococcus pneumoniae isolated from clinical materials (author's transl)].","finding":"","journal":"The Japanese journal of antibiotics","studyType":"Clinical Study"}],"tags":[{"label":"mydecamycin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"J01FA03","category":"atc"},{"label":"Active","category":"status"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"aboren","offLabel":[],"synonyms":["mydecamycin","aboren","Espinomycin A","Medecamycin A1","medemycin","Medemycin A1","midecamycin","Midecamycin A1","Platenomycin B1","rubimycin","turimycin"],"timeline":[],"approvals":[],"brandName":"Aboren","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"mydecamycin","explanation":"Imagine your cells are like factories that produce proteins. Aboren is like a tool that blocks a specific step in the factory's production line, which can help slow down the growth of certain cells. This can be useful in treating diseases where cells are growing too quickly.","oneSentence":"Aboren works by inhibiting a specific cellular process.","technicalDetail":"Aboren is a mydecamycin, a class of compounds that have been shown to inhibit the production of proteins by binding to the ribosome, a complex molecular machine that reads genetic instructions and builds proteins."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1861","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=mydecamycin","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:52:04.728810","biosimilars":[],"competitors":[{"drugName":"erythromycin","drugSlug":"erythromycin","fdaApproval":"1964-06-24","genericCount":39,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"troleandomycin","drugSlug":"troleandomycin","fdaApproval":"1969-05-27","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"clarithromycin","drugSlug":"clarithromycin","fdaApproval":"1991-10-31","genericCount":20,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"azithromycin","drugSlug":"azithromycin","fdaApproval":"1991-11-01","genericCount":31,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"dirithromycin","drugSlug":"dirithromycin","fdaApproval":"1995-06-19","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"telithromycin","drugSlug":"telithromycin","fdaApproval":"2004-04-01","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"mydecamycin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"erythromycin","brandName":"erythromycin","genericName":"erythromycin","approvalYear":"1964","relationship":"same-class"},{"drugId":"troleandomycin","brandName":"troleandomycin","genericName":"troleandomycin","approvalYear":"1969","relationship":"same-class"},{"drugId":"clarithromycin","brandName":"clarithromycin","genericName":"clarithromycin","approvalYear":"1991","relationship":"same-class"},{"drugId":"azithromycin","brandName":"azithromycin","genericName":"azithromycin","approvalYear":"1991","relationship":"same-class"},{"drugId":"dirithromycin","brandName":"dirithromycin","genericName":"dirithromycin","approvalYear":"1995","relationship":"same-class"},{"drugId":"telithromycin","brandName":"telithromycin","genericName":"telithromycin","approvalYear":"2004","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"005381","UNII":"N34Z0Y5UH7","CHEBI":"CHEBI:31845","INN_ID":"3461","RXNORM":"30005","UMLSCUI":"C0066531","ChEMBL_ID":"CHEMBL1908336","KEGG_DRUG":"D01339","DRUGBANK_ID":"DB13456","PUBCHEM_CID":"5282169","SNOMEDCT_US":"703378009","MESH_SUPPLEMENTAL_RECORD_UI":"C026483"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":3,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"J01FA03","allCodes":["J01FA03"]},"biosimilarFilings":[],"recentPublications":[{"date":"1979 Feb","pmid":"297201","title":"[Comparison of the effect of ampicillin, ceftezole and mydecamycin on experimentally prepared pyoderma (author's transl)].","journal":"Shigaku = Odontology; journal of Nihon Dental College"},{"date":"1977 Aug","pmid":"275736","title":"[A study on absorption and excretion of healthy adults given mydecamycin (medemycin) capsules or granule (author's transl)].","journal":"Shigaku = Odontology; journal of Nihon Dental College"},{"date":"1977 Feb","pmid":"16149","title":"[Antibiotic susceptibility of Streptococcus pneumoniae isolated from clinical materials (author's transl)].","journal":"The Japanese journal of antibiotics"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Aboren (mydecamycin) is a small molecule drug of the mydecamycin class, but specific details about its target and mechanism of action are unknown. Its commercial status, including FDA approval and patent status, is also unclear. As a result, there is limited information available about its approved indications, half-life, bioavailability, and generic manufacturers. Further research is needed to fully understand Aboren's properties and potential uses. Its safety considerations and potential side effects are also unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}